Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries
<p>TMEM16A defines calcium-activated chloride current in pulmonary arterial endothelial cells (PAECs). (<b>a</b>) Western blot showing TMEM16A expression in donor PAECs, pulmonary arterial smooth muscle cells (PASMCs) and human lung homogenate (hLH) (N = 2–3 patients). Vinculin served as loading control. (<b>b</b>) Representative whole-cell, Ca<sup>2+</sup>-activated Cl<sup>−</sup> current (I<sub>ClCa</sub>) traces (left) and normalized current-voltage (I-V) relationships measured with voltage clamp in PAECs showing the effect of benzbromarone (Bbr) (right). (<b>c</b>) Calculated Bbr-sensitive current in donor PAECs and PASMCs. Figures were generated with <span class="html-italic">n</span> = 5–13 cells from healthy donors. (<b>d</b>,<b>e</b>) Representative isometric tension measurements and quantification showing endothelial contribution of Bbr effectiveness on U46619 pre-constricted mouse pulmonary arteries with either endothelium removed (no EC; d) or incubation with 300 µm L-NAME (<b>e</b>) (<span class="html-italic">n</span> = 4–7). ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001, ANOVA with Bonferroni post-hoc test, data are presented as mean ± s.e.m.</p> "> Figure 1 Cont.
<p>TMEM16A defines calcium-activated chloride current in pulmonary arterial endothelial cells (PAECs). (<b>a</b>) Western blot showing TMEM16A expression in donor PAECs, pulmonary arterial smooth muscle cells (PASMCs) and human lung homogenate (hLH) (N = 2–3 patients). Vinculin served as loading control. (<b>b</b>) Representative whole-cell, Ca<sup>2+</sup>-activated Cl<sup>−</sup> current (I<sub>ClCa</sub>) traces (left) and normalized current-voltage (I-V) relationships measured with voltage clamp in PAECs showing the effect of benzbromarone (Bbr) (right). (<b>c</b>) Calculated Bbr-sensitive current in donor PAECs and PASMCs. Figures were generated with <span class="html-italic">n</span> = 5–13 cells from healthy donors. (<b>d</b>,<b>e</b>) Representative isometric tension measurements and quantification showing endothelial contribution of Bbr effectiveness on U46619 pre-constricted mouse pulmonary arteries with either endothelium removed (no EC; d) or incubation with 300 µm L-NAME (<b>e</b>) (<span class="html-italic">n</span> = 4–7). ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001, ANOVA with Bonferroni post-hoc test, data are presented as mean ± s.e.m.</p> "> Figure 2
<p>TMEM16A accounts for increased Ca<sup>2+</sup>-activated Cl<sup>−</sup> current in IPAH PAECs. Immunofluorescence staining of (<b>a</b>) 3D precision cut lung slices (PCLS), (<b>b</b>) lung sections and (<b>c</b>) PAECs obtained from healthy donor lungs and patients suffering from IPAH (BP = antibody blocking peptide, scale bar = 50 µm for PCLS, 50 µm for PAECs and 50 µm for lung sections). (<b>d</b>) The effect of Bbr on representative whole-cell I<sub>ClCa</sub> traces (left) and normalized current-voltage relationships (right) measured with voltage clamp in donor and IPAH PAECs (Veh<sub>I</sub>/Bbr<sub>I</sub> = IPAH PAECs perfused with vehicle or Bbr; Veh<sub>D</sub>/Bbr<sub>D</sub> = donor PAECs perfused with vehicle or Bbr). (<b>e</b>) Comparison of the Ca<sup>2+</sup>-activated Cl<sup>−</sup> current density of donor and IPAH PAECs at 120 mV. Figures were generated with <span class="html-italic">n</span> = 12–13 cells from at least N = 4 patient samples. # <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.0001, ANOVA with Bonferroni post-hoc test, data are presented as mean ± s.e.m.</p> "> Figure 3
<p>Upregulation of TMEM16A in human PAECs. (<b>a</b>) Immunofluorescence staining of TMEM16A in PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (BP = antibody blocking peptide; scale bar = 20 µm). (<b>b</b>) Representative whole-cell I<sub>ClCa</sub> traces (left) and normalized current-voltage relationships (right) measured with voltage-clamp showing the effect of Bbr in donor PAECs transfected with Ctrl<sup>Ad</sup>. (<b>c</b>) Representative whole-cell I<sub>ClCa</sub> traces (left) and normalized current-voltage relationships (right) measured with voltage-clamp showing the effect of Bbr in donor PAECs transfected with Ano1<sup>Ad</sup> and overexpressing TMEM16A. (<b>d</b>) Consecutive, calculated Bbr-sensitive current comparing primary PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup>. Figures were generated with 8–13 cells from N = 2 healthy donors, data are presented as mean ± s.e.m.</p> "> Figure 3 Cont.
<p>Upregulation of TMEM16A in human PAECs. (<b>a</b>) Immunofluorescence staining of TMEM16A in PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (BP = antibody blocking peptide; scale bar = 20 µm). (<b>b</b>) Representative whole-cell I<sub>ClCa</sub> traces (left) and normalized current-voltage relationships (right) measured with voltage-clamp showing the effect of Bbr in donor PAECs transfected with Ctrl<sup>Ad</sup>. (<b>c</b>) Representative whole-cell I<sub>ClCa</sub> traces (left) and normalized current-voltage relationships (right) measured with voltage-clamp showing the effect of Bbr in donor PAECs transfected with Ano1<sup>Ad</sup> and overexpressing TMEM16A. (<b>d</b>) Consecutive, calculated Bbr-sensitive current comparing primary PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup>. Figures were generated with 8–13 cells from N = 2 healthy donors, data are presented as mean ± s.e.m.</p> "> Figure 4
<p>TMEM16A-mediated membrane depolarization disrupts Ca<sup>2+</sup> dynamics of human PAECs. (<b>a</b>) Fluorometric measurements indicating shift in relative resting membrane potential (E<sub>m</sub>) of donor PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> using DiBAC<sub>4</sub>(3) dye. (<b>b</b>) Representative traces depict changes in intracellular Ca<sup>2+</sup> detected in PAECs transfected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup>. (<b>c</b>–<b>e</b>) The effect of TMEM16A overexpression on cytosolic baseline Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>), store depletion and Ca<sup>2+</sup> influx using Fura-2 in donor PAECs infected with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (BHQ = butylhydroquinone). Figures were generated with 80-116 cells from N = 3 healthy donors. * <span class="html-italic">p</span> < 0.05, *** <span class="html-italic">p</span> < 0.001, paired (<b>a</b>) and unpaired t-tests (<b>c</b>–<b>e</b>).</p> "> Figure 5
<p>Enhanced TMEM16A mediates metabolic changes of PAECs. (<b>a</b>–<b>b</b>) Seahorse mitochondrial stress test profiles of TMEM16A-overexpressing primary PAECs showing the ratio of oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) OCR/ECAR. (<b>c</b>) Proliferation of human PAECs overexpressing TMEM16A measured with thymidine incorporation (<span class="html-italic">n</span> = 5). (<b>d</b>,<b>e</b>) Cas3/Cas7 apoptosis assay and cell-cycle analysis of human PAECs overexpressing TMEM16A. (STS = staurosporin). (<b>f</b>) Western blots of PAECs infected with TMEM16A-overexpressing Ano1<sup>Ad</sup> or control Ctrl<sup>Ad</sup> with quantifications of PCNA, cleaved PARP/PARP and Cyclin D1. Figures were generated with 13 separate sets of experiments. * <span class="html-italic">p</span> < 0.05, ratio-paired (<b>a</b>) or paired t-test.</p> "> Figure 5 Cont.
<p>Enhanced TMEM16A mediates metabolic changes of PAECs. (<b>a</b>–<b>b</b>) Seahorse mitochondrial stress test profiles of TMEM16A-overexpressing primary PAECs showing the ratio of oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) OCR/ECAR. (<b>c</b>) Proliferation of human PAECs overexpressing TMEM16A measured with thymidine incorporation (<span class="html-italic">n</span> = 5). (<b>d</b>,<b>e</b>) Cas3/Cas7 apoptosis assay and cell-cycle analysis of human PAECs overexpressing TMEM16A. (STS = staurosporin). (<b>f</b>) Western blots of PAECs infected with TMEM16A-overexpressing Ano1<sup>Ad</sup> or control Ctrl<sup>Ad</sup> with quantifications of PCNA, cleaved PARP/PARP and Cyclin D1. Figures were generated with 13 separate sets of experiments. * <span class="html-italic">p</span> < 0.05, ratio-paired (<b>a</b>) or paired t-test.</p> "> Figure 6
<p>Increased TMEM16A activity causes angiogenic dysfunction. (<b>a</b>) Representative pictures of PAECs wound healing assay, expressing either Ano1<sup>Ad</sup> or control Ctrl<sup>Ad</sup>, taken after 24, 36 and 48 h (scale bar = 200 µm). (<b>b</b>) Quantification of the wound healing assay. (<b>c</b>) Matrigel tube-formation assay with representative bright-field (BF) and mCherry fluorescence pictures of Ano1<sup>Ad</sup> or Ctrl<sup>Ad</sup>-infected PAECs (scale bar = 200 µm). (<b>d</b>) Quantification showing the number of branching points in comparison to Ctrl<sup>Ad</sup>. Figures were generated with 4 separate sets of experiments with triplicate in each group. ** <span class="html-italic">p</span> < 0.01, *** <span class="html-italic">p</span> < 0.001, (<b>b</b>) ANOVA with Bonferroni post-hoc test, (<b>d</b>) paired t-test.</p> "> Figure 7
<p>Elevated TMEM16A activity alters ERK1/2 signaling. (<b>a</b>) Western blots showing protein levels of p38, Akt and SAPK/JNK obtained from of PAECs infected with either Ano1<sup>Ad</sup> or control Ctrl<sup>Ad</sup>. Figures were generated with 6 samples. (<b>b</b>) Western blots showing ERK1/2 pathway activation in PAECs infected with either Ano1<sup>Ad</sup> or Ctrl<sup>Ad</sup> with quantification. Figures were generated with 6 samples. * <span class="html-italic">p</span> < 0.05, ratio-paired t-test.</p> "> Figure 8
<p>Elevated TMEM16A activity disturbs eNOS activation: (<b>a</b>) Noninduced nitric oxide levels and ACh-induced nitric oxide production of control (Ctrl<sup>Ad</sup>) and TMEM16A-overexpressing (Ano1<sup>Ad</sup>) human PAECs. Figures were generated with 8 sets of experiments with quadruplicate in each group and normalized to protein content. (<b>b</b>) Western blots showing ACh-induced changes in eNOS phosphorylation of Ctrl<sup>Ad</sup> and Ano1<sup>Ad</sup>-infected donor PAECs with quantification following the eNOS phosphorylation pattern at activatory Ser1177 and inhibitory Thr495 sites after 5, 15 and 30 min of ACh stimulation. (<b>c</b>) Quantification of basal, noninduced level of eNOS phosphorylation at Ser1177 and Thr495 as well as phosphorylation of Ser1177 15 min after ACh stimulation. Figures were generated with 6 samples. * <span class="html-italic">p</span> < 0.05, *** <span class="html-italic">p</span> < 0.001, ratio-paired t-test.</p> "> Figure 9
<p>Enhanced TMEM16A results in reduced ACh-induced vasorelaxation of human donor pulmonary arteries. (<b>a</b>) Western blot of healthy donor pulmonary artery infected with either Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> with quantification of TMEM16A overexpression (right). (<b>b</b>) Immunofluorescence staining of donor 3D, precision-cut lung slices (PCLSs) infected either with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (scale bar = Width = 1257.93 µm, Height = 1257.93 µm, Depth = 82.00 µm for Ctrl<sup>Ad</sup> and 247.00 µm for Ano1<sup>Ad</sup>). (<b>c</b>) Representative isometric tension measurements showing ACh-mediated vasorelaxation of U46619 pre-constricted donor pulmonary arteries (PAs) infected with either Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (left) and quantification of the results (right) showing 2–3 PAs from the same donor in both groups. (<b>d</b>) The effect of TMEM16A overexpression on 30 µM ACh-induced vasorelaxation of 300 nM U46619 preconstricted healthy donor pulmonary arteries. Figure was generated with 7 pairs of vessels taken from N = 3 donors. Unpaired t-test.</p> "> Figure 9 Cont.
<p>Enhanced TMEM16A results in reduced ACh-induced vasorelaxation of human donor pulmonary arteries. (<b>a</b>) Western blot of healthy donor pulmonary artery infected with either Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> with quantification of TMEM16A overexpression (right). (<b>b</b>) Immunofluorescence staining of donor 3D, precision-cut lung slices (PCLSs) infected either with Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (scale bar = Width = 1257.93 µm, Height = 1257.93 µm, Depth = 82.00 µm for Ctrl<sup>Ad</sup> and 247.00 µm for Ano1<sup>Ad</sup>). (<b>c</b>) Representative isometric tension measurements showing ACh-mediated vasorelaxation of U46619 pre-constricted donor pulmonary arteries (PAs) infected with either Ctrl<sup>Ad</sup> or Ano1<sup>Ad</sup> (left) and quantification of the results (right) showing 2–3 PAs from the same donor in both groups. (<b>d</b>) The effect of TMEM16A overexpression on 30 µM ACh-induced vasorelaxation of 300 nM U46619 preconstricted healthy donor pulmonary arteries. Figure was generated with 7 pairs of vessels taken from N = 3 donors. Unpaired t-test.</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Human Lung Samples
2.2. Cell Isolation and Culture
2.2.1. Donor and IPAH PAECs
2.2.2. PASMCs
2.3. Precision-Cut Lung Slices (PCLS)
2.4. Overexpression of TMEM16A
2.4.1. Cell Preparation
2.4.2. Isolated Pulmonary Arteries and Precision-Cut Lung Slices (PCLS)
2.5. Immunofluorescence Staining
2.5.1. Human Lung sections
2.5.2. Precision-Cut Lung Slices (PCLS)
2.5.3. Human PAECs
2.6. Analysis of Protein Expression
2.7. Measurement of Whole-Cell Ca2+-Activated Cl− Current (IClCa)
2.8. Live Cell Ca2+ Imaging
2.9. DAF-DM-Mediated Nitric Oxide Measurement
2.10. Wound Healing Assay
2.11. Pulmonary Arterial Isometric Tension Measurements
2.12. Measuring Cell Metabolic State
2.13. Matrigel Tube-Formation Assay
2.14. Assessment of Cell Proliferation In Vitro
2.15. Assessment of Cell Resting Membrane Potential In Vitro
2.16. Assessment of Cell Cas3/Cas7 Activation In Vitro
2.17. Cell-Cycle Analysis
2.18. qRT-PCR
2.19. Statistical Analysis
3. Results
3.1. TMEM16A Shapes Pulmonary Arterial Vascular Tone
3.2. TMEM16A Accounts for Increased Ca2+-Activated Cl− Current in IPAH PAECs
3.3. Increased TMEM16A Disrupts Cl− and Ca2+ Homeostasis of Human PAECs
3.4. Enhanced TMEM16A Activity Promotes Endothelial Dysfunction
3.5. Increased TMEM16A Disrupts Induced Activation of eNOS
3.6. TMEM16A Upregulation in Donor Pulmonary Arteries Reduces Acetylcholine-Induced Vasorelaxation
4. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Campinho, P.; Vilfan, A.; Vermot, J. Blood Flow Forces in Shaping the Vascular System: A Focus on Endothelial Cell Behavior. Front. Physiol. 2020, 11, 552. [Google Scholar] [CrossRef]
- Huertas, A.; Guignabert, C.; Barberà, J.A.; Bärtsch, P.; Bhattacharya, J.; Bhattacharya, S.; Bonsignore, M.R.; Dewachter, L.; Dinh-Xuan, A.T.; Dorfmüller, P.; et al. Pulmonary vascular endothelium: The orchestra conductor in respiratory diseases. Eur. Respir. J. 2018, 51, 1700745. [Google Scholar] [CrossRef]
- Humbert, M.; Guignabert, C.; Bonnet, S.; Dorfmüller, P.; Klinger, J.R.; Nicolls, M.R.; Olschewski, A.J.; Pullamsetti, S.S.; Schermuly, R.T.; Stenmark, K.R.; et al. Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives. Eur. Respir. J. 2019, 53, 1801887. [Google Scholar] [CrossRef] [Green Version]
- Noordegraaf, A.V.; Chin, K.M.; Haddad, F.; Hassoun, P.M.; Hemnes, A.R.; Hopkins, S.R.; Kawut, S.M.; Langleben, D.; Lumens, J.; Naeije, R. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: An update. Eur. Respir. J. 2019, 53, 1801900. [Google Scholar] [CrossRef]
- Lambert, M.; Capuano, V.; Olschewski, A.; Sabourin, J.; Nagaraj, C.; Girerd, B.; Weatherald, J.; Humbert, M.; Antigny, F. Ion channels in pulmonary hypertension: A therapeutic interest? Int. J. Mol. Sci. 2018, 19, 3162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, X.J.; Wang, J.; Juhaszova, M.; Gaine, S.P.; Rubin, L.J. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998, 351, 726–727. [Google Scholar] [CrossRef]
- Nagaraj, C.; Tang, B.; Bálint, Z.; Wygrecka, M.; Hrzenjak, A.; Kwapiszewska, G.; Stacher, E.; Lindenmann, J.; Weir, E.K.; Olschewski, H.; et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur. Respir. J. 2013, 41, 85–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Antigny, F.; Hautefort, A.; Meloche, J.; Belacel-Ouari, M.; Manoury, B.; Rucker-Martin, C.; Péchoux, C.; Potus, F.; Nadeau, V.; Tremblay, E.; et al. Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation 2016, 133, 1371–1385. [Google Scholar] [CrossRef] [PubMed]
- Olschewski, A.; Li, Y.; Tang, B.; Hanze, J.; Eul, B.; Bohle, R.M.; Wilhelm, J.; Morty, R.E.; Brau, M.E.; Weir, E.K.; et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ. Res. 2006, 98, 1072–1080. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.; Fantozzi, I.; Remillard, C.V.; Landsberg, J.W.; Kunichika, N.; Platoshyn, O.; Tigno, D.D.; Thistlethwaite, P.A.; Rubin, L.J.; Yuan, J.X.J. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. USA 2004, 101, 13861–13866. [Google Scholar] [CrossRef] [Green Version]
- Large, W.A.; Wang, Q. Characteristics and physiological role of the Ca2+-activated Cl− conductance in smooth muscle. Am. J. Physiol. Cell Physiol. 1996, 271, C435–C454. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.D.; Cho, H.; Koo, J.Y.; Tak, M.H.; Cho, Y.; Shim, W.S.; Park, S.P.; Lee, J.; Lee, B.; Kim, B.M.; et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008, 455, 1210–1215. [Google Scholar] [CrossRef]
- Hwang, S.J.; Blair, P.J.A.; Britton, F.C.; O’Driscoll, K.E.; Hennig, G.; Bayguinov, Y.R.; Rock, J.R.; Harfe, B.D.; Sanders, K.M.; Ward, S.M. Expression of anoctamin 1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. J. Physiol. 2009, 587, 4887–4904. [Google Scholar] [CrossRef] [PubMed]
- Rock, J.R.; O’Neal, W.K.; Gabriel, S.E.; Randell, S.H.; Harfe, B.D.; Boucher, R.C.; Grubb, B.R. Transmembrane protein 16A (TMEM16A) is a Ca2+-regulated Cl− secretory channel in mouse airways. J. Biol. Chem. 2009, 284, 14875–14880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schenk, L.K.; Buchholz, B.; Henke, S.F.; Michgehl, U.; Daniel, C.; Amann, K.; Kunzelmann, K.; Pavenstädt, H. Nephron-specific knockout of TMEM16A leads to reduced number of glomeruli and albuminuria. Am. J. Physiol. Ren. Physiol. 2018, 315, F1777–F1786. [Google Scholar] [CrossRef]
- Hong, G.S.; Lee, S.H.; Lee, B.; Choi, J.H.; Oh, S.J.; Jang, Y.; Hwang, E.M.; Kim, H.; Jung, J.; Kim, I.B.; et al. ANO1/TMEM16A regulates process maturation in radial glial cells in the developing brain. Proc. Natl. Acad. Sci. USA 2019, 116, 12494–12499. [Google Scholar] [CrossRef] [Green Version]
- Pedemonte, N.; Galietta, L.J.V. Structure and function of tmem16 proteins (anoctamins). Physiol. Rev. 2014, 94, 419–459. [Google Scholar] [CrossRef] [Green Version]
- Papp, R.; Nagaraj, C.; Zabini, D.; Nagy, B.M.; Lengyel, M.; Maurer, D.S.; Sharma, N.; Egemnazarov, B.; Kovacs, G.; Kwapiszewska, G.; et al. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2019, 53, 1800965. [Google Scholar] [CrossRef]
- Allawzi, A.M.; Vang, A.; Clements, R.T.; Jhun, B.S.; Kue, N.R.; Mancini, T.J.; Landi, A.K.; Terentyev, D.; O-Uchi, J.; Comhair, S.A.; et al. Activation of anoctamin-1 limits pulmonary endothelial cell proliferation via p38–Mitogen-activated protein Kinase–dependent apoptosis. Am. J. Respir. Cell Mol. Biol. 2018, 58, 658–667. [Google Scholar] [CrossRef]
- Stulnig, G.; Frisch, M.T.; Crnkovic, S.; Stiegler, P.; Sereinigg, M.; Stacher, E.; Olschewski, H.; Olschewski, A.; Frank, S. Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells. Atherosclerosis 2013, 230, 406–413. [Google Scholar] [CrossRef]
- Zabini, D.; Nagaraj, C.; Stacher, E.; Lang, I.M.; Nierlich, P.; Klepetko, W.; Heinemann, A.; Olschewski, H.; Bálint, Z.; Olschewski, A. Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction. PLoS ONE 2012, 7, e43793. [Google Scholar] [CrossRef] [PubMed]
- Grynkiewicz, G.; Poenie, M.; Tsien, R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440–3450. [Google Scholar] [PubMed]
- Jain, P.P.; Leber, R.; Nagaraj, C.; Leitinger, G.; Lehofer, B.; Olschewski, H.; Olschewski, A.; Prassl, R.; Marsh, L.M. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries. Int. J. Nanomed. 2014, 9, 3249–3261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nilius, B.; Droogmans, G. Ion channels and their functional role in vascular endothelium. Physiol. Rev. 2001, 81, 1415–1459. [Google Scholar] [CrossRef] [PubMed]
- Olschewski, A.; Olschewski, H.; Bräu, M.E.; Hempelmann, G.; Vogel, W.; Safronov, B.V. Basic electrical properties of in situ endothelial cells of small pulmonary arteries during postnatal development. Am. J. Respir. Cell Mol. Biol. 2001, 25, 285–290. [Google Scholar] [CrossRef]
- Ma, M.M.; Gao, M.; Guo, K.M.; Wang, M.; Li, X.Y.; Zeng, X.L.; Sun, L.; Lv, X.F.; Du, Y.H.; Wang, G.L.; et al. TMEM16A Contributes to Endothelial Dysfunction by Facilitating Nox2 NADPH Oxidase-Derived Reactive Oxygen Species Generation in Hypertension. Hypertension 2017, 69, 892–901. [Google Scholar] [CrossRef]
- Zhou, C.; Wu, S. T-type calcium channels in pulmonary vascular endothelium. Microcirculation 2006, 13, 645–656. [Google Scholar] [CrossRef]
- Zhang, B.; Naik, J.S.; Jernigan, N.L.; Walker, B.R.; Resta, T.C. Reduced membrane cholesterol limits pulmonary endothelial Ca2+ entry after chronic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 2017, 312, H1176–H1184. [Google Scholar] [CrossRef]
- Braunstein, T.H.; Inoue, R.; Cribbs, L.; Oike, M.; Ito, Y.; Holstein-Rathlou, N.H.; Jensen, L.J. The role of L- and T-type calcium channels in local and remote calcium responses in rat mesenteric terminal arterioles. J. Vasc. Res. 2009, 46, 138–151. [Google Scholar] [CrossRef]
- Li, J.; Cubbon, R.M.; Wilson, L.A.; Amer, M.S.; McKeown, L.; Hou, B.; Majeed, Y.; Tumova, S.; Seymour, V.A.L.; Taylor, H.; et al. Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation. Circ. Res. 2011, 108, 1190–1198. [Google Scholar] [CrossRef] [Green Version]
- Jousset, H.; Malli, R.; Girardin, N.; Graier, W.F.; Demaurex, N.; Frieden, M. Evidence for a receptor-activated Ca2+ entry pathway independent from Ca2+ store depletion in endothelial cells. Cell Calcium 2008, 43, 83–94. [Google Scholar] [CrossRef] [PubMed]
- Estrada, I.A.; Donthamsetty, R.; Debski, P.; Zhou, M.H.; Zhang, S.L.; Yuan, J.X.J.; Han, W.; Makino, A. STIM1 restores coronary endothelial function in type 1 diabetic mice. Circ. Res. 2012, 111, 1166–1175. [Google Scholar] [CrossRef] [PubMed]
- Concepcion, A.R.; Vaeth, M.; Wagner, L.E.; Eckstein, M.; Hecht, L.; Jun, Y.; Crottes, D.; Seidl, M.; Shin, H.P.; Weidinger, C.; et al. Store-operated Ca2+ entry regulates Ca2+-activated chloride channels and eccrine sweat gland function. J. Clin. Investig. 2016, 126, 4303–4318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.; Zou, L.; Ma, K.; Yu, J.; Wu, H.; Wei, M.; Xiao, Q. Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer. Mol. Cancer 2017, 16, 152. [Google Scholar] [CrossRef] [PubMed]
- Cabrita, I.; Benedetto, R.; Fonseca, A.; Wanitchakool, P.; Sirianant, L.; Skryabin, B.V.; Schenk, L.K.; Pavenstädt, H.; Schreiber, R.; Kunzelmann, K. Differential effects of anoctamins on intracellular calcium signals. FASEB J. 2017, 31, 2123–2134. [Google Scholar] [CrossRef]
- Polet, F.; Feron, O. Endothelial cell metabolism and tumour angiogenesis: Glucose and glutamine as essential fuels and lactate as the driving force. J. Intern. Med. 2013, 273, 156–165. [Google Scholar] [CrossRef]
- Eelen, G.; De Zeeuw, P.; Simons, M.; Carmeliet, P. Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 2015, 116, 1231–1244. [Google Scholar] [CrossRef]
- Nagy, B.M.; Kovacs, G.; Tornyos, A.; Svehlikova, E.; Foris, V.; Nagaraj, C.; Kwapiszewska, G.; Pieber, T.R.; Olschewski, A.; Olschewski, H. No indication of insulin resistance in idiopathic PAH with preserved physical activity. Eur. Respir. J. 2020, 55, 1901228. [Google Scholar] [CrossRef]
- Yang, H.; Huang, L.Y.; Zeng, D.Y.; Huang, E.W.; Liang, S.J.; Tang, Y.B.; Su, Y.X.; Tao, J.; Shang, F.; Wu, Q.Q.; et al. Decrease of intracellular chloride concentration promotes endothelial cell inflammation by activating nuclear factor-κB pathway. Hypertension 2012, 60, 1287–1293. [Google Scholar] [CrossRef] [Green Version]
- Fleming, I.; Busse, R. Signal transduction of eNOS activation. Cardiovasc. Res. 1999, 43, 532–541. [Google Scholar] [CrossRef] [Green Version]
- Vanhoutte, P.M.; Zhao, Y.; Xu, A.; Leung, S.W.S. Thirty Years of Saying NO: Sources, Fate, Actions, and Misfortunes of the Endothelium-Derived Vasodilator Mediator. Circ. Res. 2016, 119, 375–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Förstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eroglu, E.; Saeedi Saravi, S.S.; Sorrentino, A.; Steinhorn, B.; Michel, T. Discordance between eNOS phosphorylation and activation revealed by multispectral imaging and chemogenetic methods. Proc. Natl. Acad. Sci. USA 2019, 116, 20210–20217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dinh-Xuan, A.T. Endothelial modulation of pulmonary vascular tone. Eur. Respir. J. 1992, 5, 757–762. [Google Scholar] [CrossRef] [PubMed]
- Masri, F.A.; Xu, W.; Comhair, S.A.A.; Asosingh, K.; Koo, M.; Vasanji, A.; Drazba, J.; Anand-Apte, B.; Erzurum, S.C. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293, L548–L554. [Google Scholar] [CrossRef] [Green Version]
- Taraseviciene-Stewart, L.; Kasahara, Y.; Alger, L.; Hirth, P.; Mahon, G.M.; Waltenberger, J.; Voelkel, N.F.; Tuder, R.M. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001, 15, 427–438. [Google Scholar] [CrossRef]
- Abe, K.; Toba, M.; Alzoubi, A.; Ito, M.; Fagan, K.A.; Cool, C.D.; Voelkel, N.F.; McMurtry, I.F.; Oka, M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010, 121, 2747–2754. [Google Scholar] [CrossRef] [Green Version]
- Shiwarski, D.J.; Shao, C.; Bill, A.; Kim, J.; Xiao, D.; Bertrand, C.A.; Seethala, R.S.; Sano, D.; Myers, J.N.; Ha, P.; et al. To “grow” or “go”: TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clin. Cancer Res. 2014, 20, 4673–4688. [Google Scholar] [CrossRef] [Green Version]
- Kaneko, F.T.; Arroliga, A.C.; Dweik, R.A.; Comhair, S.A.; Laskowski, D.; Oppedisano, R.; Thomassen, M.J.; Erzurum, S.C. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1998, 158, 917–923. [Google Scholar] [CrossRef]
- Mason, N.A.; Springall, D.R.; Burke, M.; Pollock, J.; Mikhail, G.; Yacoub, M.H.; Polak, J.M. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J. Pathol. 1998, 185, 313–318. [Google Scholar] [CrossRef]
- Zhao, Y.Y.; Zhao, Y.D.; Mirza, M.K.; Huang, J.H.; Potula, H.H.; Vogel, S.M.; Brovkovych, V.; Yuan, J.X.; Wharton, J.; Malik, A.B. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J. Clin. Investig. 2009, 119, 2009–2018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mam, V.; Tanbe, A.F.; Vitali, S.H.; Arons, E.; Christou, H.A.; Khalil, R.A. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther. 2010, 332, 455–562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, Y.; Kongsuphol, P.; Hug, M.; Ousingsawat, J.; Witzgall, R.; Schreiber, R.; Kunzelmann, K. Calmodulin-dependent activation of the epithelial calcium-dependent chloride channel TMEM16A. FASEB J. 2011, 25, 1058–1068. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Skofic Maurer, D.; Zabini, D.; Nagaraj, C.; Sharma, N.; Lengyel, M.; Nagy, B.M.; Frank, S.; Klepetko, W.; Gschwandtner, E.; Enyedi, P.; et al. Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries. Cells 2020, 9, 1984. https://doi.org/10.3390/cells9091984
Skofic Maurer D, Zabini D, Nagaraj C, Sharma N, Lengyel M, Nagy BM, Frank S, Klepetko W, Gschwandtner E, Enyedi P, et al. Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries. Cells. 2020; 9(9):1984. https://doi.org/10.3390/cells9091984
Chicago/Turabian StyleSkofic Maurer, Davor, Diana Zabini, Chandran Nagaraj, Neha Sharma, Miklós Lengyel, Bence M. Nagy, Saša Frank, Walter Klepetko, Elisabeth Gschwandtner, Péter Enyedi, and et al. 2020. "Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries" Cells 9, no. 9: 1984. https://doi.org/10.3390/cells9091984